Hotel group Beaumierhas completed the acquisition of three hotels in Wengen, in the canton of Berne, Switzerland. The hotels are located in the center of the village. Beaumier took over the three hotels in Switzerland’
Tags :Baker McKenzie
Baker McKenzie advised the Roth Group, a portfolio company of the Patrimonium Private Equity Fund, in taking over Lausanne-based Lambda technique d’isolation or the Lambda Group. The Roth Group is thus strengthening its presence
Baker McKenzie Switzerland advised the shareholders of Sauter, Bachmann (“Sauter Bachmann”) with regard to the succession solution for shareholder Martin Sauter, who will retire on 1 January 2023. SIC Group is taking over Martin Sauter’s share
SEBA Bank (“SEBA”) successfully completes its Series C funding round, raising CHF 110 million through the issuance of participation certificates (non-voting shares). The financing round was co-led by a consortium of specialized blockchain and fintech investors,
Baker McKenzie advised NZZ (Neue Zürcher Zeitung) and Architonic ArchDaily, the online community for design and architecture, on the acquisition of international online magazine Designboom. Together, the two companies will form DAAily Platforms, provider
Occlutech Holding, a specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of Swedish Depositary Receipts (SDRs) worth SEK 450 million (
Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
Baker McKenzie advised Galenica Group (Galenica) on the sale and leaseback of the property at its headquarters in Berne to a Credit Suisse Asset Management real estate fund for around CHF 40 million. ADVISORING TEAM Baker
Baker McKenzie advised Deka Immobilien Investment (“Deka”) on its successful acquisition of the EK2 building, a major warehouse and logistics building near Geneva, from a Compagnie des Parcs subsidiary. The EK2 building is a ground
Merck, a global science and technology company, has entered into an agreement to acquire Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases. With this step, Merck expands its neurology pipeline with the
